Keywords: evolutec, rev131, fails, ph, ii, inflammation, trial

Evolutec's rEV131 fails in Ph II inflammation trial

Article | 15 January 2007

Print This

UK biopharmaceutical firm Evolutec says that, as a result of a failed Phase II trial, no further investment will be ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in